STAT’s biotech roundup reports that several pharmacy benefit managers (PBMs) have agreed to display price comparisons that reference TrumpRx. The item presents this as a shift in how PBMs present drug-pricing information to patients or plan members, indicating an industry move to make comparisons involving the TrumpRx benchmark or program more visible.
The source excerpt does not include specifics on which PBMs are participating, how the prices will be displayed (for example, on formularies, member portals, or pharmacist-facing systems), whether the display will be voluntary or contractually required, or the timeline for implementation. The article also does not provide the text of any agreement, regulatory guidance, or data on how the change is expected to affect out-of-pocket costs or prescribing behavior. Those details were not reported in the available source material.
The roundup notes that the Food and Drug Administration yesterday approved an oral treatment from Bristol Myers Squibb called Zenbexus for advanced multiple myeloma. The piece frames this approval as the debut of a new class of medicine for the blood cancer and highlights that U.S. regulators cleared the drug using a more sensitive measure of remission.
The article excerpt emphasizes the regulatory milestone but stops short of reporting supporting clinical data in the accessible text. It does not include pivotal trial results, patient populations, safety findings, the exact surrogate or sensitive remission measure used, recommended dosing, approved indication language, or any postmarketing requirements that may accompany accelerated approval. Those trial and labeling details were behind STAT’s paywall and were not provided in the excerpt.
STAT’s brief also reports that Novartis prevailed in a key patent dispute in the United Kingdom concerning Entresto, the company’s heart-failure therapy. The item presents the decision as a legal win for Novartis, implying continued intellectual property protection or an important defense of its patent estate in that market.
The source excerpt does not describe the legal arguments, the specific patent claims at issue, the court’s reasoning, whether the ruling blocks generic competition, or how the verdict will affect market access and pricing in the U.K. Those particulars were not reported in the available portion of the article.
This roundup was filed by Meghana Keshavan, STAT’s biotech correspondent, and dated Aug. 14, 2026. It appears in STAT’s The Readout newsletter and is published as a STAT+ exclusive. Multiple sections of the full article and linked in-depth pieces are gated behind the STAT+ subscription.
The excerpt includes STAT+ subscription prompts and pricing information, and it links to related STAT coverage on topics such as drug prices, biotechnology, and drug development. The piece is positioned as a short-form collection of biotech news items rather than a single deeply reported feature in the freely available text.
No contractual or technical details about the PBM agreement to display TrumpRx prices were provided in the excerpt: participating PBMs, required display formats, enforcement mechanisms, or expected timelines were not reported.
For Zenbexus, the article did not include clinical trial identifiers, numerical efficacy or safety outcomes, the surrogate or remission measure definition, population inclusion/exclusion criteria, or postapproval commitments. The specific labeling language adopted by the FDA and proposed warnings or contraindications were not in the available text.
Regarding the Novartis/Entresto patent decision, the excerpt did not supply the court’s opinion, the patents or claims adjudicated, whether the ruling prevents generic entry, or any appeals status.
The article is an aggregated biotech news roundup with several items summarized; much of the deeper reporting and detailed data are indicated as subscriber-only content. Where the source excerpt lacks information, this rewrite does not add or infer details.
If you would like, I can summarize any related STAT stories that are referenced in the excerpt (for example, the separate STAT+ piece on Bristol’s approval or other linked reports) — but I can only use and summarize the text that is accessible in the source you provide or public reporting you supply.